Genmab announced updated Phase 2 trial results for petosemtamab, an investigational antibody, showing objective response rates of 75% in first-line and 67% in second-line metastatic colorectal cancer patients. The drug demonstrated promising durability and depth of response, especially in left-sided tumors with an 81% response rate. These findings support ongoing global Phase 3 trials aiming to confirm petosemtamab's benefit in treating metastatic colorectal cancer. The treatment was generally well-tolerated, with manageable side effects and no treatment-related deaths reported.
Genmab's updated Phase 2 trial results for petosemtamab provide context for health sector investors. For readers following health stocks, here is Pluang's market snapshot as of Oct 25, 2026 15:51 WIB: of 150 priced US health-sector stocks, 44 rose and 105 fell. Notable movers include TVTX at USD 50.05 (-4.54%), ADPT at USD 25.51 (+4.51%), and AMWL at USD 13.57 (-4.37%).
Tango, a global live-streaming platform, has donated tens of thousands of dollars to support FRIDA Ukraine's mobile cancer screening program. This initiative brings essential cancer detection and preventive healthcare services directly to underserved...
California's upcoming AI safety mandate, effective May 15, 2027, is creating tension with federal military cybersecurity rules under the Defense Federal Acquisition Regulation Supplement (DFARS). Veteran-led engineering groups have developed advanced...
Greg Abel highlighted that every one-point increase in BNSF's profit margin translates to about $230 million in additional cash flow for Berkshire Hathaway. This underscores the significant impact BNSF's operational efficiency has on Berkshire's over...
NovaBridge Biosciences announced updated Phase 1b data for givastomig, a bispecific antibody for first-line metastatic gastroesophageal adenocarcinoma, showing durable clinical benefits with an 8 mg/kg dose selected for further development. The data,...
BlackRock's iShares Bitcoin Trust (IBIT) attracted $565.7 million in net Bitcoin inflows from October 19 to 23, marking it the top U.S. spot Bitcoin ETF performer during this period. Despite some outflows late in the week, the fund ended with strong ...
